Biogen/Elan Seek First-Line Claim For Tysabri In JCV-Negative MS Patients
This article was originally published in The Pink Sheet Daily
Given the risks of progressive multifocal leukoencephalopathy, a proposed restriction appears aimed at blunting the potentially unfavorable impact that longer duration of use in the first-line setting would have on natalizumab’s risk/benefit profile.
You may also be interested in...
The MS powerhouse got approval for its fourth treatment for the disease; the drug will help bolster the franchise while sales of some of the other drugs are eroded.
Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.
Biogen Idec reported steady progress in the clinic for four late-stage programs, including hemophilia. Recent bumps include a three-month delay for the MS product BG-12, but nothing that would derail its Phase III pipeline.